Evidence over hype on GLP-1s and cardiometabolic health
Evidence-based deep dives on GLP-1s, obesity medicine, and longevity. From a board-certified obesity medicine physician. Free, twice a week.
Most Recent
Get the evidence in your inbox
Evidence over hype on GLP-1s, twice a week.
GLP1
+2
Jul 21, 2026
•
4 min read
I Put Twelve GLP-1 Trials on One Page
The evidence that actually holds up in 2026 — weight loss, heart, kidney, muscle, and the myths that should have died already. Free one-page reference inside.
Lipids
+1
Jul 18, 2026
•
2 min read
The PCSK9 Pill Is Here. The Needle Was the Barrier.
The FDA approved the first oral PCSK9 inhibitor — antibody-class LDL-C lowering from a once-daily tablet. Here is what it does, and the one thing it hasn't proven yet.
GLP1
+2
Jul 11, 2026
•
6 min read
SPECIAL EDITION: Nobody Asked.
A new JAMA secret-shopper study bought 45 GLP-1 prescriptions online. Most arrived in a day. Some in under 5 minutes. Almost none asked the questions that keep patients safe. I have watched this happen from the inside, and I know exactly why.
Get In Touch
Evidence over hype on GLP-1s and cardiometabolic health
Evidence-based deep dives on GLP-1s, obesity medicine, and longevity. From a board-certified obesity medicine physician. Free, twice a week.